Several additional murine studies highlight the potential for improved anti-tumor response with combination therapy using anti-IL-6 with ICI, suggesting IL-6 blockade could decouple ICI anti-tumor immunity from toxicity (75). The gene discussed is IL6; the disease is neoplasm.